Pharmaceutical company Charles River Laboratories International Inc (NYSE:CRL) on Tuesday announced a new agreement with Pluristyx Inc, a provider of tools, technologies and services for the development of cell therapies.
The collaboration grants Charles River access to a range of stem cell lines, including embryonic stem (ES) cells and induced pluripotent stem cells (iPSCs), boosting its research tools for therapeutic development.
Charles River will distribute Pluristyx's iPSCs, including genetically engineered variants, and a selection of ES cell lines, all sourced with full donor consent and approval of the US National Institutes of Health (NIH) making them eligible for use in NIH-funded research.
This partnership aims to accelerate therapeutic development by providing researchers with specialised cells for disease modelling and therapy advancement.
ES and iPS cells serve as invaluable resources for studying disease mechanisms and developing effective treatments. With this expansion, Charles River strengthens its global leadership in supplying essential biomaterials, driving progress in various fields including drug discovery, toxicity studies, regenerative medicine and cell therapy development.
Sanofi commits USD18m to boost diversity in clinical studies
GSK PLC announces acceptance of NDA for gepotidacin by US FDA
Anixa Biosciences administers second dose of CAR-T therapy to individual patient
Saniona reaches milestone in Boehringer Ingelheim partnership
Lipella granted patent for innovative drug delivery technology
SystImmune receives FDA clearance for Phase 1 trial of novel AML therapy
PTC Therapeutics' sepiapterin receives US FDA target regulatory action date
PharmAbcine's PMC-403 Phase one clinical trial single ascending dose cohort receives safety approval
RedHill Biopharma's opaganib selected for Ebola treatment development by BARDA
Exelixis and Merck collaborate on clinical development of zanzalintinib
BD launches automated reagent kit to streamline single-cell discovery studies
Transgene's Phase II trial of TG4001 falls short of primary objective
Lundbeck agrees to acquire Longboard Pharmaceuticals to enhance neuroscience pipeline